Blog

In the latest close session, Robinhood Markets, Inc. (HOOD) was down 6.63% at $82.47. The stock fell short of the S&P 500, which registered a loss of 2.65% for the day. At the same time, the Dow

AI and chip stocks tanked on Friday, sending the Nasdaq tumbling 4%. The bulls could dig their heels in again early next week. But there’s no doubt that a larger pullback will happen at some point

Radical New Technology Could Hand Investors Huge Gains

Quantum Computing is the next technological revolution, and it could be even more advanced than AI.

While some believed the

Radical New Technology Could Hand Investors Huge Gains

Quantum Computing is the next technological revolution, and it could be even more advanced than AI.

While some believed the

Radical New Technology Could Hand Investors Huge Gains

Quantum Computing is the next technological revolution, and it could be even more advanced than AI.

While some believed the

Radical New Technology Could Hand Investors Huge Gains

Quantum Computing is the next technological revolution, and it could be even more advanced than AI.

While some believed the

Radical New Technology Could Hand Investors Huge Gains

Quantum Computing is the next technological revolution, and it could be even more advanced than AI.

While some believed the

Friday, June 5, 2026The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Caterpillar

Investors in California Resources Corporation CRC need to pay close attention to the stock based on moves in the options market lately. That is because the June 18, 2026 $40 Call had some of the

Investors in Solaris Energy Infrastructure, Inc. SEI need to pay close attention to the stock based on moves in the options market lately. That is because the June 18, 2026, $57.50 Call had some of

AI spending remains concentrated around advanced computing infrastructure, benefiting companies involved in chip design, manufacturing, packaging and memory. Yet, recent market actions suggest that

With June now underway, investors may benefit from a proactive stock selection approach by identifying stocks trading within well-defined price ranges and showing breakout opportunities. In this

Shares of Gartner IT have had a decent run over the past month. The stock has risen 9.1% against the industry's 3% decline. The Zacks S&P 500 composite has gained 1.6% during the said time frame.

Cencora COR is trying to do more than move pharmaceuticals from point A to point B. The company is leaning into higher-value services that help manufacturers reach community sites of care, while

Glaukos Corporation’s GKOS growth prospects are supported by the continued expansion of interventional glaucoma, growing clinical and commercial synergies between iDose TR and iStent infinite, and

Affirm Holdings, Inc. AFRM has renewed and expanded its funding partnership with Canada Pension Plan Investment Board (CPP Investments). Under the new 24-month forward-flow agreement, CPP

Celanese Corporation CE is shifting production from its Engineered Materials compounding facility in Ulsan, South Korea, to its plants in Nanjing and Shenzhen, China, and Silvassa, India. The move

ICON plc ICLR is moving through a credibility and earnings reset that is now as much about controls as it is about demand. The company has laid out the scope of its accounting findings, flagged

American Tower AMT shares have risen 10.5% in the year-to-date period compared with the industry’s 9.0% growth.

This Zacks Rank #3 (Hold) company is well-positioned to benefit from long-term growth

Block’s XYZ Cash App, the popular peer-to-peer payment platform, is introducing a new way to pay with the launch of Cash App Tags. These NFC-enabled physical payment accessories allow customers to

Teladoc Health, Inc. TDOC is a pioneer and global leader in the telemedicine industry. It has a broad international presence, serving clients, supporting medical operations and reaching members

Agenus AGEN is taking an uncommon route to validate demand for its lead immuno-oncology combination, botensilimab plus balstilimab (BOT+BAL), before a traditional launch. Instead of waiting for full

Agenus AGEN sits at a classic biotech crossroads. On one side is BOT+BAL, a lead immuno-oncology program being tested in a late-stage setting where current checkpoint inhibitors have historically

Agenus AGEN centered its investment case on botensilimab plus balstilimab (BOT+BAL), a checkpoint combination being advanced in refractory microsatellite stable (MSS)/mismatch repair proficient

Investors are always trying to time the market. They want to get in at the lows and get out at the highs. While this simplistic goal sounds easy, it is almost impossible to achieve.Regardless of